Literature DB >> 24722063

Clinical, morphologic, phenotypic, and genetic evidence of cyclin D1-positive diffuse large B-cell lymphomas with CYCLIN D1 gene rearrangements.

Darius Juskevicius1, Christian Ruiz, Stephan Dirnhofer, Alexandar Tzankov.   

Abstract

Overexpression of cyclin D1 in diffuse large B-cell lymphomas (DLBCLs) is observable in about 5% of cases and is linked to gains of additional CYCLIN D1 gene copies or deregulation at the mRNA level. All cyclin D1-positive DLBCL cases reported so far lack the canonical t(11;14)(q13;q32) translocation that is a genetic hallmark and the primary cause of cyclin D1 overexpression in mantle cell lymphoma (MCL). Using standard histologic and genetic techniques, complemented with genome-wide aberration analysis by array comparative genomic hybridization, we characterized 2 exceptional cases of blastoid B-cell lymphomas with cyclin D1 overexpression, both bearing genetic rearrangements in the CYCLIN D1 gene locus. One of them had a t(11;14)(q13;q32) translocation and featured morphology, immunophenotype, and genetic copy number aberrations typical of DLBCL. The second case had a complex t(4;11;14) translocation, but the other features were intermediate between DLBCL and MCL and did not allow unambiguous classification in any of the current diagnostic lymphoma categories. On the basis of these findings, we conclude that detection of t(11;14) should not preclude a diagnosis of cyclin D1-positive DLBCL when all other parameters are in agreement with such a diagnosis. Moreover, a yet unacknowledged diagnostic "gray zone" may exist between DLBCL and MCL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24722063     DOI: 10.1097/PAS.0000000000000120

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

1.  Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.

Authors:  D Juskevicius; T Lorber; J Gsponer; V Perrina; C Ruiz; F Stenner-Liewen; S Dirnhofer; A Tzankov
Journal:  Leukemia       Date:  2016-05-20       Impact factor: 11.528

2.  Analysis of PI3K pathway components in human cancers.

Authors:  Jamila Daragmeh; Waseim Barriah; Bashar Saad; Hilal Zaid
Journal:  Oncol Lett       Date:  2016-03-08       Impact factor: 2.967

3.  Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.

Authors:  Alexandar Tzankov; Nora Leu; Simone Muenst; Darius Juskevicius; Dirk Klingbiel; Christoph Mamot; Stephan Dirnhofer
Journal:  J Hematol Oncol       Date:  2015-06-14       Impact factor: 17.388

4.  Clinicopathologic features of 112 cases with mantle cell lymphoma.

Authors:  Dong-Mei Zhou; Gang Chen; Xiong-Wei Zheng; Wei-Feng Zhu; Bao-Zhen Chen
Journal:  Cancer Biol Med       Date:  2015-03       Impact factor: 4.248

5.  Prognostic efficacy of the human B-cell lymphoma prognostic genes in predicting disease-free survival (DFS) in the canine counterpart.

Authors:  Mohamad Zamani-Ahmadmahmudi; Sina Aghasharif; Keyhan Ilbeigi
Journal:  BMC Vet Res       Date:  2017-01-09       Impact factor: 2.741

6.  Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge.

Authors:  Da Gao; Zach Liu
Journal:  Biomark Res       Date:  2019-06-03

7.  Four genetic lymphoma-specific events (MYC, BCL2, BCL6 and CCND1) identified in a high grade B lymphoma case.

Authors:  A Ittel; C Hélias; M P Wissler; E Toussaint; L Miguet; M P Chenard; L Monier; C Gervais; L Mauvieux
Journal:  Blood Cancer J       Date:  2015-12-11       Impact factor: 11.037

8.  High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations.

Authors:  V Pillonel; D Juskevicius; C K Y Ng; A Bodmer; A Zettl; D Jucker; S Dirnhofer; A Tzankov
Journal:  Leukemia       Date:  2018-02-28       Impact factor: 11.528

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.